Trial Profile
A study to examine the influence of repaglinide on the 'incretin effect' and oxidative damage associated with postprandial.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 28 Aug 2011 New trial record